INT8413

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.78
First Reported 1981
Last Reported 2010
Negated 5
Speculated 6
Reported most in Abstract
Documents 248
Total Number 254
Disease Relevance 110.17
Pain Relevance 108.58

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nuclear envelope (Ptgs1) aging (Ptgs1) Golgi apparatus (Ptgs1)
endoplasmic reticulum (Ptgs1) cytoplasm (Ptgs1) lipid binding (Ptgs1)
Anatomy Link Frequency
spinal 11
spinal cord 11
brain 8
cerebellum 5
blood 4
Ptgs1 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Inflammation 496 100.00 Very High Very High Very High
aspirin 199 100.00 Very High Very High Very High
COX2 188 100.00 Very High Very High Very High
cOX1 118 100.00 Very High Very High Very High
COX-2 inhibitor 104 100.00 Very High Very High Very High
Analgesic 85 100.00 Very High Very High Very High
cytokine 79 100.00 Very High Very High Very High
antagonist 46 100.00 Very High Very High Very High
diclofenac 39 100.00 Very High Very High Very High
agonist 39 100.00 Very High Very High Very High
Disease Link Frequency Relevance Heat
INFLAMMATION 701 100.00 Very High Very High Very High
Cancer 181 100.00 Very High Very High Very High
Adhesions 70 100.00 Very High Very High Very High
Necrosis 25 100.00 Very High Very High Very High
Cv Unclassified Under Development 14 99.92 Very High Very High Very High
Colon Cancer 102 99.88 Very High Very High Very High
Hyperalgesia 115 99.84 Very High Very High Very High
Schizophrenia 36 99.80 Very High Very High Very High
Atherosclerosis 7 99.80 Very High Very High Very High
Stress 185 99.76 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
These data are compatible with the hypothesis that the sensory abnormalities observed in patients with RP may depend on estradiol-induced changes in SPGN, resulting in a sympathetically-dependent production of cyclooxygenase products of arachidonic acid.
Gene_expression (production) of cyclooxygenase associated with congenital anomalies
1) Confidence 0.78 Published 1989 Journal Brain Res. Section Abstract Doc Link 2546646 Disease Relevance 0.78 Pain Relevance 0.65
Systemic acetylsalicylic acid and mefenamic acid, in doses known to produce cyclooxygenase inhibition, produced limited or no analgesia using a duodenal distension model and a behavioral scale for assessment.
Neg (inhibition) Gene_expression (produce) of cyclooxygenase associated with aspirin and analgesia
2) Confidence 0.78 Published 1989 Journal Pharmacol. Biochem. Behav. Section Abstract Doc Link 2780782 Disease Relevance 0.07 Pain Relevance 0.68
Western blotting demonstrated general expression of cyclooxygenase-1 in test tissues and cyclooxygenase-2 within the brain and cerebellum.
Gene_expression (expression) of cyclooxygenase in brain
3) Confidence 0.76 Published 2004 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 15148345 Disease Relevance 0.07 Pain Relevance 0.47
This is consistent with the apparent impossibility for the expression of cyclooxygenase active protein from cyclooxygenase-3 mRNA in the rat.
Gene_expression (expression) of cyclooxygenase
4) Confidence 0.76 Published 2004 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 15148345 Disease Relevance 0.05 Pain Relevance 0.34
Western blotting demonstrated general expression of cyclooxygenase-1 in test tissues and cyclooxygenase-2 within the brain and cerebellum.
Gene_expression (expression) of cyclooxygenase in brain
5) Confidence 0.76 Published 2004 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 15148345 Disease Relevance 0.07 Pain Relevance 0.48
Reverse transcription-polymerase chain reaction analysis of aorta, brain, cerebellum, heart, and lung showed general expression of cyclooxygenase-1 and cyclooxygenase-3 mRNA and particular expression of cyclooxygenase-2 mRNA in brain and cerebellum.
Gene_expression (expression) of cyclooxygenase in lung
6) Confidence 0.76 Published 2004 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 15148345 Disease Relevance 0.08 Pain Relevance 0.46
Reverse transcription-polymerase chain reaction analysis of aorta, brain, cerebellum, heart, and lung showed general expression of cyclooxygenase-1 and cyclooxygenase-3 mRNA and particular expression of cyclooxygenase-2 mRNA in brain and cerebellum.
Gene_expression (expression) of cyclooxygenase-3 mRNA in lung
7) Confidence 0.76 Published 2004 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 15148345 Disease Relevance 0.08 Pain Relevance 0.48
The results of the present studies also reveal that melatonin may influence the expression of Cu-Zn SOD, catalase, cyclooxygenase as well as alpha-actinin whose levels were found to be altered, following piroxicam treatment.
Gene_expression (expression) of cyclooxygenase
8) Confidence 0.75 Published 2004 Journal J. Pineal Res. Section Abstract Doc Link 15009511 Disease Relevance 0.14 Pain Relevance 0.22
By Northern analysis, only PGHS-2 is expressed by the immortalized rat osteoblastic cell line, Py1a, while only PGHS-1 is expressed by the rat osteosarcoma cell line, ROS 17/2.8.
Gene_expression (expressed) of PGHS-1 associated with osteoporosis and osteogenic sarcomas
9) Confidence 0.70 Published 1997 Journal J. Bone Miner. Res. Section Abstract Doc Link 9258749 Disease Relevance 0.36 Pain Relevance 0.55
A 5-week study was carried out in rats using a leukotriene biosynthesis inhibitor (MK-886; 3-[1-(4-chlorobenzyl)-3-t-butylthio-5-isopropylindol-2-yl]-2,2- dimethylpropanoic acid) at a dose of 300 mg.kg-1 x day-1, this being sufficient to produce > 90% inhibition of ex vivo leukotriene B4 synthesis in rat blood, and a cyclooxygenase inhibitor (indomethacin, 4 and 6 mg.kg-1 x day-1) to ascertain whether inhibition of leukotriene biosynthesis would potentiate or inhibit the toxicity associated with the administration of nonsteroidal anti-inflammatory drugs (NSAIDs), in particular the gastrointestinal damage.
Gene_expression (produce) of cyclooxygenase in blood associated with toxicity, inflammation and cinod
10) Confidence 0.67 Published 1993 Journal Can. J. Physiol. Pharmacol. Section Abstract Doc Link 8143238 Disease Relevance 0.32 Pain Relevance 0.25
IMPLICATIONS: Spinal injection of the alpha2-adrenergic agonist clonidine and the cyclooxygenase inhibitor ketorolac results in a synergistic interaction for antinociception in normal animals, suggesting that the combination of these drugs will enhance rather than detract from the analgesia of either alone.
Gene_expression (injection) of cyclooxygenase in Spinal associated with antinociception, acular, agonist, analgesia and clonidine
11) Confidence 0.67 Published 2003 Journal Anesth. Analg. Section Abstract Doc Link 12505951 Disease Relevance 0 Pain Relevance 1.88
Although both alpha2-adrenergic agonists and cyclooxygenase inhibitors produce analgesia, their exact sites of action and interaction remain unclear.
Gene_expression (produce) of cyclooxygenase associated with agonist and analgesia
12) Confidence 0.67 Published 2003 Journal Anesth. Analg. Section Abstract Doc Link 12505951 Disease Relevance 0 Pain Relevance 1.27
The potency difference is similar to that for inhibition of cyclooxygenase in brain tissue and supports the hypothesis that cyclooxygenase products are involved in prolonged spinal nociceptive transmission.
Gene_expression (products) of cyclooxygenase in spinal associated with nociception and potency
13) Confidence 0.67 Published 1994 Journal Eur. J. Pharmacol. Section Abstract Doc Link 8050472 Disease Relevance 0.10 Pain Relevance 0.33
Furthermore, the effect of a high dose of 25 mg/kg of the S(+) enantiomer on release of cyclooxygenase products from the various tissues was much longer lasting than that of an identical dose of the R(-) enantiomer.
Gene_expression (products) of cyclooxygenase
14) Confidence 0.67 Published 1991 Journal Prostaglandins Section Abstract Doc Link 1801061 Disease Relevance 0.22 Pain Relevance 0.10
With the S(+) enantiomer and the racemate dose-dependent inhibition of release of cyclooxygenase products of arachidonate metabolism in all tissues tested was observed, while release of leukotriene (LT) C4 was inhibited in gastric mucosa, but not in jejunum and lung.
Gene_expression (products) of cyclooxygenase in lung
15) Confidence 0.67 Published 1991 Journal Prostaglandins Section Abstract Doc Link 1801061 Disease Relevance 0.10 Pain Relevance 0
In the present study, we examined the changes of cyclooxygenase-1 and cyclooxygenase-2 protein expression in several regions of the CNS associated with pain perception, and the role of spinal cyclooxygenase activity in the development of allodynia following nerve injury.
Gene_expression (expression) of cyclooxygenase-1 in spinal associated with pain, nervous system injury and allodynia
16) Confidence 0.67 Published 2000 Journal Neuroscience Section Abstract Doc Link 10842019 Disease Relevance 0.72 Pain Relevance 0.54
In contrast, cyclooxygenase-1 protein was not detectable in any of the neural tissues examined one, three, and 14 days after nerve injury.
Neg (not) Gene_expression (detectable) of cyclooxygenase-1 protein in neural associated with nervous system injury
17) Confidence 0.67 Published 2000 Journal Neuroscience Section Abstract Doc Link 10842019 Disease Relevance 0.97 Pain Relevance 0.81
Effects of cyclooxygenase products of arachidonic acid metabolism on cutaneous nociceptive threshold in the rat.
Gene_expression (products) of cyclooxygenase associated with nociception and nociceptor
18) Confidence 0.66 Published 1990 Journal Brain Res. Section Title Doc Link 2128200 Disease Relevance 0.61 Pain Relevance 0.59
The edema was accompanied by an increase in 5-lipoxygenase products, and the hyperalgesia coincided with the formation of both cyclooxygenase and 5-lipoxygenase products.
Gene_expression (products) of cyclooxygenase associated with pressure and volume under development and hyperalgesia
19) Confidence 0.66 Published 1987 Journal Biochem. Pharmacol. Section Abstract Doc Link 3103625 Disease Relevance 0.61 Pain Relevance 0.51
MATERIALS AND METHODS: Cerebral infarcted rats underwent cumulative intravenous administration of the selective cyclooxygenase-1 inhibitor SC-560 (Sigma), the selective cyclooxygenase-2 inhibitor rofecoxib (Kemprotec, Middlesbrough, United Kingdom) or the nonselective cyclooxygenase inhibitor FYO-750 hourly plus a single intravenous administration of SC-560, rofecoxib or SC-560 plus rofecoxib.
Gene_expression (selective) of cyclooxygenase-1
20) Confidence 0.66 Published 2010 Journal J. Urol. Section Body Doc Link 20022033 Disease Relevance 0.19 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox